Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How has the herceptin market size changed in recent years, and what is the outlook ahead?
The herceptin market size has grown strongly in recent years. It will grow from $7.10 billion in 2024 to $7.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to regulatory approvals, rising breast cancer incidence, advancements in monoclonal antibody technology, strong clinical trial outcomes, and increasing healthcare expenditure.
The herceptin market size is expected to see strong growth in the next few years. It will grow to $9.59 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to the expansion of biosimilars, increasing adoption of targeted therapies, rising healthcare access in emerging markets, ongoing R&D in oncology, and growing prevalence of HER2-positive cancers. Major trends in the forecast period include the development of antibody-drug conjugates, advancement in biosimilar formulations, integration of AI in drug discovery, personalized medicine approaches, and improving drug delivery systems.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24236&type=smp
What are the top economic and technological drivers pushing herceptin market growth?
The increasing incidence of breast cancer is expected to propel the growth of the herceptin market going forward. Breast cancer is a type of cancer that forms in the cells of the breast, usually starting in the milk ducts or lobules. It includes invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The rise in breast cancer is partly due to lifestyle changes, such as increased alcohol consumption, poor diet, and lack of physical activity, which contribute to a higher risk. As more people are diagnosed with breast cancer, particularly HER2-positive cases, the demand for effective targeted therapies such as herceptin continues to rise. For instance, in January 2025, according to the American Cancer Society, a US-based cancer organization, an estimated 319,750 new cases of breast cancer are expected to be reported in 2025, with approximately 42,680 deaths projected from the disease. Thus, the increasing incidence of breast cancer is driving the expansion of the herceptin market.
How is the herceptin market segmented by product, application, and end-user?
The herceptin market covered in this report is segmented –
1) By Product: Biologic, Biosimilar
2) By Application: Breast Cancer, Gastric Cancer
3) By Payer: Commercial And Private, Public
4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy
Subsegments:
1) By Biologic: Intravenous (IV) Biologics, Subcutaneous (SC) Biologic
2) By Biosimilar: Intravenous (IV) Biosimilars, Subcutaneous (SC) Biosimilars
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/herceptin-global-market-report
What evolving trends are creating new opportunities in the herceptin market?
Major companies operating in the herceptin market are developing novel treatment options, such as innovative biosimilar products, to enhance patient access and improve therapeutic outcomes for HER2-positive cancers. Innovative biosimilar products are highly similar versions of approved biologic drugs that are developed using advanced biotechnology to ensure comparable safety, efficacy, and quality. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a biosimilar to herceptin (trastuzumab), for the treatment of HER2-overexpressing breast and gastric cancers. Biosimilars such as HERCESSI demonstrate comparable efficacy and safety to their reference biologics while potentially offering more cost-effective treatment options.
Which leading companies are dominating the herceptin market landscape?
Major companies operating in the herceptin market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Genentech Inc., Dr. Reddy’s Laboratories, Celltrion Healthcare, Mundipharma, Biocon Limited, Bio-Techne Corporation, Samsung Bioepis Co Ltd, AryoGen Pharmed, InvivoGen, Abnova Corporation, Shanghai Henlius Biotech Inc., Prestige Biopharma Pte Ltd.
Which geographic areas are expected to offer the highest growth opportunities in theherceptin market?
North America was the largest region in the herceptin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herceptin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Herceptin Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24236&type=smp
Need Customized Data On Herceptin Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24236&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
